On November 12, the official website of the State Drug Administration revealed that Eli Lilly's Class 1 new drug, ofloglilone calcium tablets, was approved for marketing in China. The drug is suitable for long-term weight management in adults with an initial body mass index meeting the following requirements based on diet control and increased exercise: ≥30 kg/m2, or ≥27 kg/m2 to <30 kg/m2 with at least one body-related complication. It is the first oral GLP-1 weight loss drug approved in China.

On November 12, the official website of the State Drug Administration revealed that Eli Lilly's Class 1 new drug, ofloglilone calcium tablets, was approved for marketing in China. The drug is suitable for long-term weight management in adults with an initial body mass index meeting the following requirements based on diet control and increased exercise: ≥30 kg/m2, or ≥27 kg/m2 to <30 kg/m2 with at least one body-related complication. It is the first oral GLP-1 weight loss drug approved in China.